REFERENCE: Lancet 2007; 370: 389-97 LUDWIG KAPPOS, University Hospital, Basel
Earlier treatment can reduce the risk of confirmed disability in patients with multiple sclerosis, according to a new study published in the Lancet. Three-year follow-up of the BENEFIT study showed favourable results among patients who began treatment with interferon beta-1b after a first event suggestive of multiple sclerosis, rather than waiting for further confirmatory events. Nicola Solomon interviewed Ludwig Kappos.
Vincent Rajkumar
Vincent Rajkumar, Divison of Hematology, Mayo Clinic
At a section of the hematology meeting talking about newly diagnosed multiple myeloma
Post a comment